首页> 外文期刊>Biochimica et biophysica acta. Molecular cell research >Inhibitory role of adiponectin peptide I on rat choroidal neovascularization
【24h】

Inhibitory role of adiponectin peptide I on rat choroidal neovascularization

机译:脂联素肽I对大鼠脉络膜新生血管的抑制作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Age-related macular degeneration (AMD) is a leading cause of central blindness in the elderly population. The wet type of AMD is characterized by extensive growth of new vessels. One of the effective strategies to treat wet AMD is to limit the choroidal neovascularization (CNV). We studied the effects of adiponectin peptide I (APNpI) on new vessel growth in laser-induced rat model of wet AMD and on rat choroidal endothelial cell (CEC) culture. CNV size and vessel density were investigated by microscopy. Immunohistochemical staining (IHC) for von Willebrand Factor (vWF), APN, APN receptors 1 (AdipoR1), 2 (AdipoR2), VEGF, VEGF receptor 2 (VEGF-R2), proliferating cell nuclear antigen (PCNA) was performed in CNV area. The mRNA expression of VEGF and VEGF-R2 in RPE-choroid was investigated by RT-PCR and real-time PCR. APNpI inhibited area of CNV by 4 fold, number of vWF positive vessels by 99% and area of subretinal tissue by 40%. The expression of VEGF and VEGF-R2 at mRNA and protein levels decreased after APNpI treatment in vivo. Proliferative index (PCNA) was 5 folds less in laser spots of APNpI treated rats compared to controls. In conclusion, APNpI inhibited formation of new vessels in rat model of CNV by decreasing VEGF, VEGF-R2 expression and cell proliferation. Thus, APNpI may have potential therapeutic use for AMD treatment since it significantly inhibited CNV.
机译:与年龄有关的黄斑变性(AMD)是老年人中枢性失明的主要原因。湿性AMD的特征在于新血管的大量生长。治疗湿性AMD的有效策略之一是限制脉络膜新血管形成(CNV)。我们研究了脂联素肽I(APNpI)对激光诱导的湿性AMD大鼠模型中新血管生长的影响以及对大鼠脉络膜内皮细胞(CEC)培养的影响。 CNV大小和血管密度通过显微镜检查。在CNV区域进行了von Willebrand因子(vWF),APN,APN受体1(AdipoR1),2(AdipoR2),VEGF,VEGF受体2(VEGF-R2),增殖细胞核抗原(PCNA)的免疫组织化学染色(IHC) 。通过RT-PCR和实时荧光定量PCR研究RPE-脉络膜中VEGF和VEGF-R2的mRNA表达。 APNpI抑制CNV面积增加4倍,vWF阳性血管数量减少99%,视网膜下组织面积减少40%。 APNpI体内处理后,VEGF和VEGF-R2在mRNA和蛋白水平的表达下降。与对照组相比,APNpI处理的大鼠的激光斑点中的增殖指数(PCNA)低5倍。总之,APNpI通过降低VEGF,VEGF-R2表达和细胞增殖来抑制CNV大鼠模型中新血管的形成。因此,APNpI可能会显着抑制CNV,因此可能在AMD治疗中具有潜在的治疗用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号